StreetAlpha
13F holdings · Q3 2026

Foresite Capital Management V

West Hollywood, CA · files as Foresite Capital Management V, LLC
Know the moment Foresite Capital Management V filesYou follow Foresite Capital Management V An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1792206

Foresite Capital Management V reported 9 stocks worth $289M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CGON (26.4%), LTGO (20.6%) and ALMS (15.1%). Compared with Q2 2026, the fund opened new positions in LTGO, added to HIMS, ODTX and NRIX and sold out of LYEL.

Latest filing: what Foresite Capital Management V did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
1 new3 added0 trimmed1 sold outBought about $68.8M · sold about $6.7M
New 1
Added 3
Trimmed 0

None

Sold out 1

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$289M−20.2% vs last quarter
Stocks held91 new · 1 sold out
Top 5 weight79.7%very concentrated
Turnover26%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
CGON
CG Oncology Inc
$76.5M26.4%1.1MNo change8 of 8
2
LTGO
Latigo Biotherapeutics
$59.5M20.6%3.6MNew position1 of 8
3
ALMS
Alumis Inc
$43.6M15.1%5.9MNo change8 of 8
4
HIMS
Hims & Hers Health Inc
$26.3M9.1%884K+146K (+20%)8 of 8
5
IRON
Disc Medicine Inc
$24.5M8.5%374KNo change8 of 8
6
PHVS
Pharvaris N V
$21.1M7.3%664KNo change3 of 8
7
ODTX
Odyssey Therapeutics, Inc.
$16.2M5.6%730K+16K (+2%)2 of 8
8
NRIX
Nurix Therapeutics Inc
$10.9M3.8%459K+194K (+73%)3 of 8
9
EIKN
Eikon Therapeutics Inc
$10.6M3.7%1.3MNo change3 of 8

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
LYEL
Lyell Immunopharma Inc
$6.7M476K

Reported value

last 8 quarters
$120MQ4 '24
$87.6MQ1 '25
$80.7MQ2 '25
$109MQ3 '25
$164MQ4 '25
$271MQ1 '26
$362MQ2 '26
$289MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Foresite Capital Management V 13F FAQ

What does Foresite Capital Management V own?

Foresite Capital Management V reported 9 stocks worth $289M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CGON (26.4%), LTGO (20.6%) and ALMS (15.1%). The table above lists every position in the filing (the top 10 without an account).

What did Foresite Capital Management V buy and sell in Q3 2026?

Compared with Q2 2026: 1 new positions, 3 added to, 0 trimmed and 1 sold out. New positions include LTGO. It sold all of LYEL.

When will Foresite Capital Management V file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Foresite Capital Management V's portfolio worth?

The Q3 2026 filing reports $289M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.